Literature DB >> 21931373

Reproductive endocrinology: triptorelin ovarian suppression during breast cancer chemotherapy.

Elizabeth S Ginsburg, Ann H Partridge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21931373     DOI： 10.1038/nrendo.2011.159

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women.

Authors:  S L Broer; M J C Eijkemans; G J Scheffer; I A J van Rooij; A de Vet; A P N Themmen; J S E Laven; F H de Jong; E R Te Velde; B C Fauser; F J M Broekmans
Journal:  J Clin Endocrinol Metab       Date:  2011-05-25       Impact factor: 5.958

2.  Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

Authors:  Bernd Gerber; Gunter von Minckwitz; Heinrich Stehle; Toralf Reimer; Ricardo Felberbaum; Nikolai Maass; Dorothea Fischer; Harald L Sommer; Bettina Conrad; Olaf Ortmann; Tanja Fehm; Mahdi Rezai; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

3.  Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.

Authors:  Lucia Del Mastro; Luca Boni; Andrea Michelotti; Teresa Gamucci; Nina Olmeo; Stefania Gori; Monica Giordano; Ornella Garrone; Paolo Pronzato; Claudia Bighin; Alessia Levaggi; Sara Giraudi; Nicola Cresti; Emanuela Magnolfi; Tiziana Scotto; Carlo Vecchio; Marco Venturini
Journal:  JAMA       Date:  2011-07-20       Impact factor: 56.272

4.  Web-based survey of fertility issues in young women with breast cancer.

Authors:  Ann H Partridge; Shari Gelber; Jeffrey Peppercorn; Ebonie Sampson; Katherine Knudsen; Marc Laufer; Randi Rosenberg; Michele Przypyszny; Alison Rein; Eric P Winer
Journal:  J Clin Oncol       Date:  2004-10-15       Impact factor: 44.544

5.  Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.

Authors:  Ahmed Badawy; Aboubakr Elnashar; Mohamed El-Ashry; May Shahat
Journal:  Fertil Steril       Date:  2008-08-03       Impact factor: 7.329

6.  Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.

Authors:  Ann H Partridge; Kathryn J Ruddy; Shari Gelber; Lidia Schapira; Mary Abusief; Meghan Meyer; Elizabeth Ginsburg
Journal:  Fertil Steril       Date:  2009-05-05       Impact factor: 7.329

7.  Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Authors:  Sandra M Swain; Jong-Hyeon Jeong; Charles E Geyer; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan Polikoff; Victor G Vogel; John K Erban; Priya Rastogi; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Stephanie R Land; Patricia A Ganz; Norman Wolmark
Journal:  N Engl J Med       Date:  2010-06-03       Impact factor: 176.079

8.  Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.

Authors:  Richard A Anderson; David A Cameron
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.